Adma Biologics Inc (ADMA) concluded trading on Wednesday at a closing price of $18.50, with 3.96 million shares of worth about $73.21 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 0.65% during that period and on March 12, 2025 the price saw a gain of about 6.63%. Currently the company’s common shares owned by public are about 236.62M shares, out of which, 228.00M shares are available for trading.
Stock saw a price change of 4.64% in past 5 days and over the past one month there was a price change of 11.04%. Year-to-date (YTD), ADMA shares are showing a performance of 7.87% which increased to 191.80% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $5.88 but also hit the highest price of $23.64 during that period. The average intraday trading volume for Adma Biologics Inc shares is 2.45 million. The stock is currently trading 12.99% above its 20-day simple moving average (SMA20), while that difference is up 10.73% for SMA50 and it goes to 14.13% higher than SMA200.
Adma Biologics Inc (NASDAQ: ADMA) currently have 236.62M outstanding shares and institutions hold larger chunk of about 86.69% of that.
The stock has a current market capitalization of $4.37B and its 3Y-monthly beta is at 0.60. PE ratio of stock for trailing 12 months is 22.72, while it has posted earnings per share of $0.81 in the same period. Its PEG reads 0.73 and has Quick Ratio of 2.90 while making debt-to-equity ratio of 0.24. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ADMA, volatility over the week remained 6.19% while standing at 5.99% over the month.
Stock’s fiscal year EPS is expected to rise by 43.56% while it is estimated to increase by 41.90% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Raymond James on July 19, 2023 offering a Strong buy rating for the stock and assigned a target price of $5 to it. Coverage by Mizuho stated Adma Biologics Inc (ADMA) stock as a Buy in their note to investors on October 13, 2022, suggesting a price target of $5 for the stock. On November 11, 2021, Raymond James Upgrade their recommendations, while on November 09, 2021, Cantor Fitzgerald Initiated their ratings for the stock with a price target of $4.50. Stock get a Buy rating from Jefferies on June 04, 2019.
